Harmony Biosciences Holdings, Inc. (HRMY): Total Liabilities
$401.41M
As of 2025-12-31
$373.84M
As of 2026-06-30
+14.0%
3-year compound annual growth
+4.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $401.41M | +18.0% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $340.05M | -1.3% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $344.46M | +27.1% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $271.03M | +9.8% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $246.94M | -25.1% | 2023-02-21, Balance as of period end |
| 2020-12-31 | $329.89M | +178.9% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $118.29M | n/a | 2021-03-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $401.41M | +18.0% |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $899.65M | +5.1% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $3.03B | +25.6% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $656.90M | +128.2% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $1.36B | -5.5% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $188.85M | +17.3% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $796.00M | -12.2% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $571.81M | -26.2% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $840.49M | -0.6% |
Compare HRMY, ANIP, IONS, MDGL side by side · Screen every company in Pharmaceutical Preparations ↗